Literature DB >> 22427559

Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes.

Yumiko Akagi-Kurashige1, Kyoko Kumagai, Kenji Yamashiro, Hideo Nakanishi, Isao Nakata, Masahiro Miyake, Akitaka Tsujikawa, Muka Moriyama, Kyoko Ohno-Matsui, Manabu Mochizuki, Ryo Yamada, Fumihiko Matsuda, Nagahisa Yoshimura.   

Abstract

PURPOSE: To investigate a potential association between VEGF gene polymorphisms and the occurrence and/or the size of choroidal neovascularization (CNV) in highly myopic eyes.
METHODS: In the case-control study for CNV occurrence, 327 highly myopic Japanese patients were enrolled. One hundred and eighty-four patients had CNV in at least one eye, and 143 did not have CNV in either eye. Of the 184 patients with CNV, 83 patients were used to evaluate an association with CNV size, and an additional 76 patients with CNV were used to confirm the association. We genotyped four tag single nucleotide polymorphisms (SNPs) and four functional SNPs previously reported to be correlated with VEGF gene expression to evaluate the associations of these eight SNPs with CNV occurrence and size. To confirm the association between CNV size and VEGF gene polymorphism, the associated SNP was genotyped in 76 additional patients with myopic CNV.
RESULTS: There was no significant association between the occurrence of myopic CNV and the SNPs in the VEGF gene (P > 0.16). Of the eight SNPs evaluated, however, rs2010963 showed significant association with CNV area (P = 0.0047). This association was successfully replicated in the additional 76 eyes with myopic CNV, and pooled analysis revealed significant association of rs2010963 with CNV size (P = 0.00078).
CONCLUSIONS: VEGF gene polymorphisms were not associated with CNV occurrence in highly myopic eyes but were significantly associated with the size of CNV, suggesting roles in the growth rather than the emergence of CNV.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427559     DOI: 10.1167/iovs.11-9405

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

Review 1.  Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.

Authors:  Yan Zhang; Qian Han; Yusha Ru; Qiyu Bo; Rui Hua Wei
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

Review 2.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

Review 3.  Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization.

Authors:  Colin S Tan; SriniVas R Sadda
Journal:  Clin Ophthalmol       Date:  2017-09-26

4.  Long-Term Natural Outcomes of Simple Hemorrhage Associated with Lacquer Crack in High Myopia: A Risk Factor for Myopic CNV?

Authors:  Bing Liu; Xiongze Zhang; Lan Mi; Ling Chen; Feng Wen
Journal:  J Ophthalmol       Date:  2018-01-24       Impact factor: 1.909

5.  Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography.

Authors:  Lu-Na Cheng; Yu-Xi Lin; Lei Liu; Xu-He Zhang; Yan-Qi Xue; Sheng-Di Zhou; Zhe-Li Liu; Han Zhang
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.